3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
114
Stomach Neoplasms
19
HER2-positive Breast Cancer
14
Neoplasms
12
Neoplasm Metastasis
12
Colorectal Neoplasms
11
Esophageal Neoplasms
9
Triple Negative Breast Neoplasms
5
Lung Neoplasms
5
Colonic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Brain Neoplasms
5
Rectal Neoplasms
4
Ovarian Neoplasms
4
Meningeal Neoplasms
4
Endometrial Neoplasms
4
Biliary Tract Neoplasms
4
Adenocarcinoma Of Esophagus
4
Uterine Cervical Neoplasms
3
Salivary Gland Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Meningeal Carcinomatosis
3
Lymphoma, Non-Hodgkin
3
Inflammatory Breast Neoplasms
3
Hematologic Neoplasms
3
Gallbladder Neoplasms
3
Breast Diseases
3
Anatomic Stage I Breast Cancer AJCC v8
3
Interventions
Cyclophosphamide
12
fludarabine phosphate
7
fludarabine
7
venetoclax
6
blinatumomab
6
Cytarabine
5
Lenalidomide
4
Dexamethasone
4
Blood Specimen Collection
4
Azacitidine
4
obinutuzumab
3
Rituximab
3
Radiotherapy
3
Melphalan
3
Immunotherapy, Adoptive
3
pembrolizumab
2
daratumumab
2
Neoadjuvant Therapy
2
Idarubicin
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sacituzumab govitecan
1
sabatolimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Trastuzumab
×
1 year
×
Clear all
NCT06663787
2026-05-13
HER2 CR
Nagoya City University
Active not recruiting
50 enrolled